$BNTC News

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate

Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Benitec To Highlight Key Clinical Results Observed To Date For OPMD Patients Enrolled Into BB-301 Phase 1b/2a Clinical Treatment Study And Potential For BB-301 To Transform Treatment Landscape For Patients With OPMD At 2026 MDA Clinical and Scientific Conference

Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden.

Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden.

HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma Announced Promising Interim Clinical Results From The BB-301 Phase 1b/2a First-in-human Study (NCT06185673) Evaluating Low Dose And High Dose BB-301 Treatment For Oculopharyngeal Muscular Dystrophy With Moderate Dysphagia

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Benitec Biopharma Inc (NASDAQ:BNTC) Stock Gains on Positive BB-301 Data Despite Q2 Earnings Miss

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate

Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade

Reported Sunday, Benitec Biopharma Reports Sustained Disease-Modifying Outcomes And Durable Responses In BB-301 Phase 1b/2a OPMD Clinical Study

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response